Kelly Gonzales
Family · San Diego, CANPI 1194109702
Payments from drug & device makers
Across 735 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- Johnson & Johnson$859
- Lilly USA, LLC$814
- plus $8K from 54 others
What the payments were for
- Food & beverage$14,681100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,681 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $40,905 |
| FarxigaDapagliflozin Propanediol | 32 | $38,735 |
| OzempicSemaglutide | 24 | $35,183 |
| EliquisApixaban | 23 | $29,506 |
| XareltoRivaroxaban | 21 | $24,832 |
| Repatha SureclickEvolocumab | 30 | $22,643 |
| TrulicityDulaglutide | 17 | $22,587 |
| JardianceEmpagliflozin | 17 | $17,943 |
| Duloxetine Hcl | 35 | $2,884 |
| Levothyroxine Sodium | 264 | $2,473 |
| Gabapentin | 114 | $2,012 |
| ValacyclovirValacyclovir Hcl | 27 | $1,980 |
| Atorvastatin Calcium | 198 | $1,922 |
| Olmesartan Medoxomil | 36 | $1,682 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $814 | $63,49356 claims |
| AstraZenecaFarxiga | $1,093 | $38,73532 claims |
| Novo NordiskOzempic | $1,005 | $35,18324 claims |
| PfizerEliquis | $267 | $29,50623 claims |
| Johnson & JohnsonXarelto | $859 | $24,83221 claims |
| Boehringer IngelheimJardiance | $599 | $17,94317 claims |
| AbbVieSynthroid | $1,424 | $63214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in San Diego
- Nancy GardettoSan Diego$394K
- Dawn MeyerSan Diego$270K
- Erin DwyerSan Diego$189K
- Lizaveta NikitsinaSan Diego$36K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Jennifer KangCerritos$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.